X4 Pharmaceuticals, Inc
About X4 Pharmaceuticals, Inc
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $35.1M
- Net income
- -$79.2M
- Total assets
- $290.5M
- Market cap
- $361.2M
- Gross margin
- 68.8%
- Operating margin
- -1423.6%
- Net margin
- -1464.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.6M
- Cost of revenue
- $797.0K
- Gross profit
- $1.8M
- Operating expenses
- $38.2M
- Operating income
- -$36.4M
- Income tax
- $310.0K
- Net income
- -$37.5M
- EPS (basic)
- $-0.19
- EPS (diluted)
- $-0.19
Balance sheet
- Total assets
- $146.4M
- Current assets
- $112.2M
- Total liabilities
- $124.3M
- Current liabilities
- $32.9M
- Shareholders’ equity
- $22.1M
Cash flow
- Operating cash flow
- -$130.9M
- Investing cash flow
- $67.0M
- Financing cash flow
- $20.3M
- Net cash flow
- -$43.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $361.2M
- EPS (diluted)
- $-0.19
- Shares outstanding
- 97.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 16, 2017
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $79.2M in FY2025.
- Revenue declined 15% from FY2020 to FY2024.
- Gross margin of 68.8%, net margin -1464.6%.
- Trading 20% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review X4 Pharmaceuticals, Inc.
Write a review
News about X4 Pharmaceuticals, Inc
News & sentiment via Polygon.io
